The 7th International Symposium on Platinum and other metal coordination compounds in Cancer Chemotherapy, ISPCC '95, organized by the European Cancer Centre, was held in Amsterdam, the Netherlands, March 1-4, 1995. As with previous ISPCC meetings, the goal of ISPCC '95 was to bring together c1inicians, clinical investigators, scientists, and laboratory workers from many disciplines to promote further collaboration and cooperation in the development of new platinum and other metal coordination compounds as weil as in new ways to use 'c1assical' drugs as cisplatin and carboplatin in the treatment of cancer. Important aspects addressed by experts in the field inc1uded the synthesis and activity of new platinum compounds, the biochemistry and molecular pharrnacology as weil as the c1inical pharrnacology of this c1ass of antineoplastic agents, an overview of current c1inical studies, one special minisymposium on the mechanisms of cell kill of platinum, and one on resistance against platinum compounds. Finally, the current status of development of nonplatinum metal complexes was discussed. This volume contains the contributions of the various speakers at ISPCC '95 and provides an up-to-date and comprehensive overview of this important c1ass of anticancer agents, ranging from synthesis and molecular pharrnacology on one hand to c1inical pharrnacology and cIinical investigations on the other hand. The Organizing Corrunittee and Editors wish to express their gratitude to the contributors to this volume, to the various organizations and pharrnaceutical companies for their generous sponsoring of ISPCC '95, and to the Plenum Publishing Company for their help in producing this volume.

Taken together the data presented in this review, and work by many other investigators, support the notion that DNA excision repair is important in a tumor cell's resistance to platinum compounds. Inhibition of this repair system by combination chemotherapy with the excision repair inhibitors HU and Ara-C produces synergistic cell kills and increased levels and persistance of DNA interstrand crosslinks. The studies with cis-DDP and ~-DDP in combination with UV induced thymine dimers suggest that there may be competition for DNA repair enzymes between the dimer and the platinum lesion. Whether the competing lesion is an intrastrand crosslink, interstrand crosslink, or platinum monoadduct (or all of these lesions) cannot be determined. The similarity between an intrastrand crosslink and a cyclobutane dimer suggests that these lesions may compete for repair. However, the increased peak levels of interstrand crosslinks, and increased persistence of these lesions at later time points suggest that this lesion may also be a substrate for the repair system. These observations may be of clinical relevance. Recently Dr. Kathy Albain of our institution has completed a Phase III I study using a 12 hour pretreatment with HU and Ara-C in patients prior to their cis-DDP therapy. She observed a significant number of responders in this trial (54). She is currently completing a second Phase IIII study substituting IV HU for the oral formulation. We anticipate initiating other clinical trials based upon these observations.

Proceedings of the Fifth International Symposium, held in Abano Terme (Padova), italy, June 29-July 2, 1987

With contributions by numerous experts

This volume reviews the experimental data on drug-radiation interactions. Special emphasis is placed on clinically-useful antitumor drugs. Particular reference is made to appropriate timing, concentration and sequencing of drug-radiation combinations. It includes discussions on the relative merits of experimental data derived from animal versus human tumors. This book also presents a section on the potential for new model systems or alternative test procedures for evaluating therapeutic benefits and cytotoxicities. Results of randomized clinical studies are reviewed with emphasis on recent studies involving protocols specifically designed to test the benefits from optimal integration of chemotherapy with radiotherapy. This book is intended for laboratory researchers in the field and clinicians interested in using the combined modality approach. It is also a useful resource for radiologists, oncologists, and all those interested in cancer research.

Leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use in treatment, as well as examining their future therapeutic prospects. Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch repair and replicative bypass, apoptosis, and the transport of platinum drugs into tumor cells. The emergent platinum drugs of the future-orally active agents, the sterically hindered ZD0473, and the polynuclear charged platinum BBR3464-are also fully considered. Timely and interdisciplinary, Platinum-Based Drugs in Cancer Therapy offers cancer therapeutics specialists an illuminating survey of every aspect of platinum drugs from mechanisms of action to toxicology, tumor resistance, and new analogs.

Advances in Anticancer Agents in Medicinal Chemistry is an exciting eBook series comprising a selection of updated articles previously published in the peer-reviewed journal Anti-Cancer Agents in Medicinal Chemistry. The second Volume of this eBook series gathers updated reviews on several classes of molecules exhibiting anticarcinogenic potential as well as some important targets for the development of novel anticancer drugs.

The idea for convening a Fourth International Symposium on Platinum Coordination Complexes in Cancer Chemotherapy was born in an assembly of researchers from the Vermont Regional Cancer Center and the Norris Cotton Cancer Center who shared a common interest in metal complexes. It was agreed by those assembled that sufficient time had passed since the Third International Symposium on Platinum Coor dination Complexes in Cancer Chemotherapy held in 1976 at the Wadley Institutes of Molecular Medicine in Dallas, Texas, during which several advances in the chemistry, biochemistry, pharmacology and clinical use of platinum complexes had occurred, to warrant a fourth symposium. Furthermore, intensive investigations in progress were bringing sophisticated methodologies to bear on the problems in the field, clinical trials were yielding interesting results, and unique approaches to cancer therapy were being designed. Therefore, an organizing committee was formed and planning culminated in the symposium which was held in Burlington, Vermont, June 22-24, 1983.

First multi-year cumulation covers six years: 1965-70.

Bio-Inorganic compounds are successfully applied as therapeutic agents since decades. Thus, scientist designed new metal complexes bearing biomolecules as ligands, investigating their potential as bioactive and therapeutic agents. This book presents a comprehensive overview on materials design, substance classes and their characterization. This book is compiled for scientists interested in medical application of bioinspired materials.